Here are the 8-K filings from Mentari Therapeutics, Inc. (MTRI) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow MTRI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MTRI filings page.
InMed Pharmaceuticals Inc. (INM) completed its merger with Mentari Therapeutics on November 6, 2026, and changed its name to Mentari Therapeutics, Inc. Immediately before closing, Pre-Merger Mentari issued common shares and pre-funded warrants for approximately $490.0 million in gross proceeds, including approximately $52.7 million of convertible-note principal and accrued interest. Former Mentari securityholders held approximately 99.0% of the combined company on a fully diluted basis after closing, compared with approximately 1.0% for former InMed securityholders.
For the three months ended September 30, 2026, Pre-Merger Mentari reported a $32.2 million net loss, versus $6.6 million for the prior-year quarter, and had generated no revenue from product sales. Cash and cash equivalents were $45.8 million as of September 30, 2026. Management said cash and proceeds from the Merger and pre-closing financing were expected to fund operating plans for at least 12 months after the financial statements were issued.